COMPARE · Reviewed July 29, 2026
NBIX vs ZTS
Verdict: Side-by-side breakdown using the Bull Rankings model. NBIX scored 87.4, ZTS scored 78.0 — NBIX leads.
Compare another set
NBIX
Neurocrine Biosciences, Inc.
87.4
$180.79 · $18.2B
fundamentals as of
Score gap
9.4
NBIX leads
ZTS
Zoetis Inc.
78
$77.93
fundamentals as of
Fundamentals, head-to-head
NBIX
ZTS
$831mC+
FCF
$2.2bB
+28.6%A-
Rev
+2.6%C
0.14B+
D/E
2.86D
27.8xB
P/E
12.8xA
0.50A
PEG
1.84C+
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
NBIX
ZTS
7% below
Price vs fair valuelower is cheaper
—
~13%/yr
Growth the price implies10-yr FCF · lower = less priced in
—
-18%
1-yr DCF upside
—
+7%
5-yr DCF upside
—
+60%
10-yr DCF upside
—
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
NBIX
Why this score
- Durable high returns
ZTS
No notable signals flagged.
The companies
NBIXNeurocrine Biosciences, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $18.2b. Trading near 52-week high of $183.50 — momentum setup, limited technical margin of safety. Revenue growing +29% — in hypergrowth territory. PEG 0.50 — paying under fair value for the growth rate. 27 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $202.17 (implying +12% upside).
Moat
Net margin 22% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 20% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 124% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
ZTSZoetis Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap n/a. Down 51% from 52-week high of $160.48 — deep drawdown territory. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $111.94 (implying +44% upside).
Moat
Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 82% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 2.86 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Down 51% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.